- US-listed companies
- Tonix Pharmaceuticals Holding Corp.
- Income statement
Tonix Pharmaceuticals Holding Corp. (TNXP) Income statement
Market cap
$122.55M
P/E ratio
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 8 | 10 |
| Revenue growth (%) | - | - | - | - | - | - | - | - | - | - | - | - | |
| Cost of revenue | - | - | - | - | - | - | - | - | - | - | - | 5 | 8 |
| Research & development | 2 | 5 | 9 | 19 | 36 | 29 | 13 | 18 | 36 | 69 | 82 | 87 | 40 |
| Selling, general & administrative | - | - | - | - | - | - | - | - | - | - | - | 35 | 40 |
| Operating margin (%) | - | - | - | - | - | - | - | - | - | - | - | ||
| Operating expenses | 6 | 13 | 24 | 28 | 48 | 39 | 21 | 29 | 51 | 92 | 112 | 126 | 147 |
| Operating income | -3,378,528 | -6,661,410 | -11 | -28 | -48 | -39 | -21 | -29 | -51 | -92 | -112 | -118 | -137 |
| Net income | -3,470,113 | -9,449,600 | -11 | -28 | -48 | -39 | -21 | -29 | -50 | -92 | -110 | -117 | -130 |
| Net income margin (%) | - | - | - | - | - | - | - | - | - | - | - | ||
| Earnings per share | - | - | - | - | - | - | - | - | - | - | -3.27 | -6.85 | -176.6 |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -3.27 | -6.85 | -176.6 |
| EBITDA | - | - | - | - | - | ||||||||
| EBITDA margin (%) | - | - | - | - | - | - | - | - | - | - | - |